Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Aclaris Therapeutics (Malvern, PA), a preclinical-stage pharmaceutical company focused on topical dermatological therapies, closed a $21M Series A financing. Participants include Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Neurovance (Cambridge, MA), a clinical-stage pharmaceutical company focused on treatments for CNS disorders such as adult attention deficit hyperactivity disorder, closed a $7M Series A financing. Participants include Novartis Venture Fund. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP […]

GnuBIO (Cambridge, MA), a developmental-stage medical device company focused on next-generation DNA sequencing, closed a $10M Series B financing. Participants were not identified. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Quantia Communications (Waltham, MA), a HealthIT company and maker of an online physician community and collaboration platform, has closed a $12M Series E. Participants include Fuse Capital. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Nuclea Biotechnologies (Pittsfield, MA) a commercial-stage diagnostic company focused on in vitro companion diagnostic assays based on gene and protein expression profiles and biomarkers associated with an individual’s tumor or specific disease state, closed a $3.4M Series B financing bringing the total round to $9.8M. Participants were not identified. Note: Closing out 1Q deals. Thanx […]

Mnemosyne Pharmaceuticals (Providence, RI) a development-stage small molecule company focused on neuropsychiatric disorders such as schizophrenia and Alzheimer’s, closed a $5.4M Series financing Participants include Access BridgeGap Ventures and Slater Technology Fund. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Vascular Magnetics (Philadelphia, PA) a development-stage medical device focused on magnetically targeted drug delivery for the treatment of peripheral artery disease, closed a $7M Series A financing. Participants include Devon Park Bioventures. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

4s3 Bioscience (Medford, MA) a preclinical-stage biotherapeutics company focused on developing genetics disease therapies for orphan neuromuscular disorders, closed a $20M Series A financing. Participants include KLP Enterprises. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

NeuroPhage Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on small molecules for protein aggregation diseases such as Alzheimer’ and Parkinson’s disease, closed a $9M Series B financing, bringing the total round to $21.4M. Participants include Merieux Developpement and Shire.

Tarsa Therapeutics (Philadelphia, PA) a clinical-stage biopharmaceutical company focused on treatments for postmenopausal osteoporosis, closed a $28 Series B financing. Participants include Foresite Capital, Novo, MVM Life Science Partners and Quaker Partners.

Stemgent (Cambridge, MA) a commercial-stage biopharmaceutical company focused on stem cell reagents and tools for stem cell researchers, closed a $6.3M Series C financing. Participants include HealthCare Ventures and Morganthaler Partners.

Mevion Medical Systems (Littleton, MA) a commercial-stage medical device company focused on proton beam radiotherapy device for cancer, closed a $45M Series G financing. Participants include ProQuest Investment, Caxton Heath Life Sciences, Venrock and CHL Medical Partners.

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...